obesity drug news today october 21 2025 glp-1 Receptor Agonists – From Evolution to Revolution GLP-1 brands: Eli Lilly is

By curbing oxidative stress and inflammatory responses, GLP-1 RAs can help protect kidney cells from damage, making these drugs particularly useful for diabetic patients with AKD

But enforcing this traditional doctrine has already failed in the United States, which is why 50% of Americans are projected to become obese by 2030

By my count there are at least seven ongoing (and one recently completed) clinical trials of GLP-1 receptor agonists for Parkinsons

The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects

Mol Neurobiol (2018) 55(4):300720

Taheri H, Malek M, Ismail-Beigi F et al (2020) Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial